White Rose Ventures, in partnership with 1855 Capital and Ben Franklin Technology Partners of Central & Northern PA, is proud to announce that Keystone Innovation Fund II has invested in Thiopoly, Inc., a Pittsburgh-based HealthTech company modernizing how medications are tracked and managed across the fast-growing world of outpatient and clinic-based care. Thiopoly is exactly the kind of company Keystone Innovation Fund II was built to back: a driven, deeply experienced founder solving a real, expensive problem in a large market, right here in Pennsylvania.

Thiopoly’s flagship product “Thio” is an IoT- and sensor-based inventory platform purpose-built for the places medicine is increasingly delivered: infusion centers, specialty pharmacies, clinic networks, and outpatient health-system sites. As care continues its long migration out of the hospital, these settings have been underserved by medication-management systems designed decades ago for inpatient pharmacies. Thio closes that gap with real-time visibility into drug inventory—no tagging, no heavy IT lift, and no upfront capital outlay—delivered as a simple subscription that frees up cash, unburdens IT, reduces waste, and gives pharmacy teams back their time.

A few of the reasons we’re excited about Thiopoly:

A market moving in Thiopoly’s direction. Care is shifting to ambulatory and clinic settings faster than the tools that support it—and the industry’s incumbents remain anchored to the hospital. Thio is purpose-built for that widening, underserved gap, giving it a clear lane in a very large market.

A product that’s already proving itself in the field. This isn’t a lab concept—Thio is deployed and delivering in real pharmacy operations. That real-world performance is echoed in an independently published case study in Pharmacy Purchasing & Products (July 2026), authored by the senior director of pharmacy at the University of Rochester Medical Center, documenting a 13-month smart-bin insulin deployment that reported 100% inventory accuracy across cycle counts, zero stockouts, improved safety and labeling compliance, and a positive first-year return on investment. Independent, third-party validation like this is a powerful signal in a market where health systems buy on proof.

A founder who knows this space cold. Doug Descalzi has spent 20+ years in medication management and health technology, including senior operating leadership at established industry players. He pairs that hard-won domain expertise with a genuine, listen-first approach to building product alongside his customers—a combination that gives us confidence in his ability to execute.

For Keystone Innovation Fund II, Thiopoly is a natural expression of the fund’s thesis: backing exceptional, driven founders building high-growth technology companies across Pennsylvania, with a return-first approach and a commitment to long-term value creation in the Commonwealth. Thiopoly also deepens the fund’s presence in Pittsburgh and Western Pennsylvania—a step in the new fund’s mission to turn regional momentum into statewide acceleration.

“Doug is the rare founder who has lived this problem from every angle — he knows the pharmacy, the technology, and the customer better than just about anyone, and it shows in how quickly Thio is earning trust in the field. Care keeps moving out of the hospital, but the tools to manage medication in those settings haven’t kept up. Thiopoly is closing that gap with something pharmacy teams actually want to use, and we’re proud to back Doug and the team as they scale it.” — Matt Rhodes, Partner, Keystone Innovation Fund II

“We are thrilled to partner with KIF as we begin deployment of our technology and build momentum.  We have a growing backlog, and access to the right capital is critical for our growth.  Investment and support from KIF will allow us to continue to build and scale.” — Doug Descalzi, Founder & CEO, Thiopoly

 

White Rose Ventures and its partners are proud to support Doug and the Thiopoly team, and look forward to sharing more from the Keystone Innovation Fund II portfolio in the months ahead.

About Thiopoly
Thiopoly, Inc. is a Pittsburgh-based HealthTech company whose “Thio” platform brings IoT-enabled, real-time inventory visibility to medication management in ambulatory and clinic-based care—helping pharmacies reduce waste, free capital, and improve productivity without added IT burden. Learn more at thiopoly.com

About Keystone Innovation Fund II
Keystone Innovation Fund II, L.P. is an early-stage venture fund managed by White Rose Ventures and 1855 Capital, in partnership with Ben Franklin Technology Partners of Central & Northern PA, backing high-growth technology companies across Pennsylvania from the earliest stages with a return-first approach.